Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: NDec - oral decitabine-tetrahydrouridine
DRUG: HU - Hydroxyurea
DRUG: Placebo

Sponsor

Novo Nordisk A/S